Abstract
In their quest to disable androgen receptor variants that drive castration-resistant prostate cancer, Richters etal. (2020) have hit upon a selective inhibitor of a transcriptional kinase that enables full-length mRNA synthesis. Drugging this essential kinase curbs tumor growth, thus making it an attractive focal target for transcription therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
